# Carboplatin

## Carboplatin inj 150mg/15mL

| TAH Drug Code      | [ICAR2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICAR2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Ovarian Cancer. First-line treatment for Advanced Ovarian Cancer, use as the initial treatment for advanced ovarian cancer, in combination with other approved chemotherapeutic agents. Secondary Treatment for Advanced Ovarian Cancer, for patients with recurrent ovarian cancer after chemotherapy as a palliative treatment, including those previously treated with cisplatin.                                                                                                                                                                                                                                                   |
| Dosing             | Monotherapy: 360mg/m2 IVD on day 1, repeated every 4 weeks. Wait until neutrophil count is >2,000 and platelet count is >100,000 before repeating. Combination with cyclophosphamide: For advanced ovarian cancer, Carboplatin - 300mg/m2 on day 1, repeated every 4 weeks for 6 cycles. Cyclophosphamide - 600mg/m2 on day 1, repeated every 4 weeks for 6 cycles. Repeat only if neutrophil count is >2,000 and platelet count is >100,000.                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Patients with a history of severe allergic reactions to carboplatin or other platinum-containing compounds. Patients with existing severe renal dysfunction, unless, in the judgment of the physician and the patient, the potential benefits of treatment are deemed to outweigh the risks. Patients suffering from severe bone marrow suppression. Patients with hemorrhagic tumors.                                                                                                                                                                                                                                                 |
| Adverse Effects    | Common: Alopecia (2-50%), Hypocalcemia (29-31%), Hypokalemia (20-28%), Hypomagnesemia (29-43%), Hyponatremia (29-47%), Abdominal pain (17%), Diarrhea (6%), Nausea (75-80%), Vomiting (65-81%), Anemia (21-90%), Leukopenia (26-71%), Neutropenia (16-67%), Thrombocytopenia (35-62%), Alkaline phosphatase above reference range (24-37%), Aspartate aminotransferase serum level above reference range (15-19%), Blood urea outside reference range (14-22%), Serum creatinine above reference range (6-10%), Pain (23%) Serious: Myelosuppression, Hypersensitivity reaction (2%), Unexplained visual loss, Visual disturbance (1%) |
| Pregnancy          | Contraindicated â€“ 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/carboplatin-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

